Ironwood Shareholders Re-Elect All Three Ironwood Director Nominees
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 31, 2018--
Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company,
today announced that, based on the vote count following the 2018 Annual
Meeting of Shareholders, shareholders voted to re-elect all three of
Ironwood’s director nominees: Lawrence Olanoff, M.D., Ph.D., Amy
Schulman and Douglas Williams, Ph.D.
Commenting on the results, Ironwood issued the following statement:
On behalf of the entire Ironwood Board of Directors and management team,
we thank our shareholders for their valuable insights and support over
these past several weeks. We look forward to continuing to engage with
our shareholders as we seek to deliver on our 2018 goals and to execute
on our intent to separate Ironwood into two focused and durable
businesses each with substantial opportunity for long-term growth and
value creation.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology
company focused on creating medicines that make a difference for
patients, building value for our fellow shareholders, and empowering our
passionate team. We are commercializing two innovative primary care
products: linaclotide, the U.S. branded prescription market leader for
adults with irritable bowel syndrome with constipation (IBS-C) or
chronic idiopathic constipation (CIC), and lesinurad, which is approved
to be taken with a xanthine oxidase inhibitor (XOI), or as a fixed-dose
combination with allopurinol, for the treatment of hyperuricemia
associated with gout. We are also advancing a pipeline of innovative
product candidates in areas of significant unmet need, including
uncontrolled gastroesophageal reflux disease, diabetic nephropathy,
heart failure with preserved ejection fraction, achalasia and sickle
cell disease. Ironwood was founded in 1998 and is headquartered
in Cambridge, Mass. For more information, please visit www.ironwoodpharma.com
or www.twitter.com/ironwoodpharma;
information that may be important to investors will be routinely posted
in both these locations.
Forward-Looking Statements
This press release contains forward-looking statements. Investors are
cautioned not to place undue reliance on these forward-looking
statements, including statements about delivering on Ironwood’s 2018
goals, and execution on and benefits of a separation. Each
forward-looking statement is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statement. Applicable risks and uncertainties include
those related to the possibility that we may not complete the separation
on the terms or timeline currently contemplated if at all, achieve the
expected benefits of a separation, and that a separation could harm our
business, results of operations and financial condition; the risk that
the transaction might not be tax-free; the risk that we may be unable to
make, on a timely or cost-effective basis, the changes necessary to
operate as independent companies; R&D Co.'s lack of independent
operating history and the risk that its accounting and other management
systems may not be prepared to meet the financial reporting and other
requirements of operating as an independent public company; the risk
that a separation may adversely impact our ability to attract or retain
key personnel; the effectiveness of development and commercialization
efforts by us and our partners; preclinical and clinical development,
manufacturing and formulation development; the risk that findings from
our completed nonclinical and clinical studies may not be replicated in
later studies; efficacy, safety and tolerability of our products and
product candidates; decisions by regulatory and judicial authorities;
the risk that we are unable to successfully commercialize lesinurad or
realize the anticipated benefits of the lesinurad transaction; the risk
that we may never get sufficient patent protection for our products and
product candidates or that we are not able to successfully protect such
patents; the outcomes in legal proceedings to protect or enforce the
patents relating to our products and product candidates, including ANDA
litigation; developments in the intellectual property landscape;
challenges from and rights of competitors or potential competitors; the
risk that our planned investments do not have the anticipated effect on
our company revenues, our products and product candidates; the risk that
we are unable to manage our operating expenses or cash use for
operations, or are unable to commercialize our products, within the
guided ranges or otherwise as expected; and the risks listed under the
heading "Risk Factors" and elsewhere in Ironwood's Quarterly Report on
Form 10-Q for the quarter ended March 31, 2018, and in our subsequent
SEC filings. These forward-looking statements (except as otherwise
noted) speak only as of the date of this press release, and Ironwood
undertakes no obligation to update these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180531005763/en/
Source: Ironwood Pharmaceuticals
Investors:
Meredith Kaya, 617-374-5082
Vice President,
Investor Relations and Corporate Communications
mkaya@ironwoodpharma.com
or
Media:
Joele
Frank, Wilkinson Brimmer Katcher
Andi Rose / Mahmoud Siddig
212-355-4449